Tables Guide:
Table 1. Characteristics of patients with relapsed or
refractory Ewing sarcoma and osteosarcoma (n=12)
Table 2. Adverse events that either occurred in
>10% of patients at any grade, or occurred at grade ≥3 in
patients with relapsed or refractory Ewing sarcoma and osteosarcoma
treated with the combination of cabozantinib, topotecan and
cyclophosphamide (n=12). Adverse events considered unrelated or unlikely
related to protocol therapy are excluded.
Table 3. Summary of objective best response in patients with
relapsed or refractory Ewing sarcoma and osteosarcoma treated with a
combination of cabozantinib, topotecan and cyclophosphamide (n=12).